GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asymchem Laboratories Tianjin Co Ltd (SZSE:002821) » Definitions » EBIT

Asymchem Laboratories Tianjin Co (SZSE:002821) EBIT : ¥2,148 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Asymchem Laboratories Tianjin Co EBIT?

Asymchem Laboratories Tianjin Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥295 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥2,148 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Asymchem Laboratories Tianjin Co's annualized ROC % for the quarter that ended in Mar. 2024 was 8.09%. Asymchem Laboratories Tianjin Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 17.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Asymchem Laboratories Tianjin Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 12.05%.


Asymchem Laboratories Tianjin Co EBIT Historical Data

The historical data trend for Asymchem Laboratories Tianjin Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asymchem Laboratories Tianjin Co EBIT Chart

Asymchem Laboratories Tianjin Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 624.36 816.86 1,200.28 3,735.47 2,563.04

Asymchem Laboratories Tianjin Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 710.04 1,221.22 558.10 73.68 295.24

Competitive Comparison of Asymchem Laboratories Tianjin Co's EBIT

For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Asymchem Laboratories Tianjin Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Asymchem Laboratories Tianjin Co's EV-to-EBIT falls into.



Asymchem Laboratories Tianjin Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,148 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Asymchem Laboratories Tianjin Co  (SZSE:002821) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Asymchem Laboratories Tianjin Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=794.232 * ( 1 - 5.14% )/( (9212.75 + 9405.234)/ 2 )
=753.4084752/9308.992
=8.09 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=19767.159 - 1538.644 - ( 9015.765 - max(0, 1800.803 - 12352.058+9015.765))
=9212.75

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=19841.423 - 1453.539 - ( 8982.65 - max(0, 1768.241 - 12110.138+8982.65))
=9405.234

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Asymchem Laboratories Tianjin Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1180.944/( ( (5358.114 + max(1455.725, 0)) + (5575.347 + max(1268.441, 0)) )/ 2 )
=1180.944/( ( 6813.839 + 6843.788 )/ 2 )
=1180.944/6828.8135
=17.29 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1998.761 + 945.347 + 271.657) - (1538.644 + 0 + 221.396)
=1455.725

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1712.927 + 992.331 + 288.751) - (1453.539 + 0 + 272.029)
=1268.441

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Asymchem Laboratories Tianjin Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=2148.236/17829.400
=12.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Asymchem Laboratories Tianjin Co EBIT Related Terms

Thank you for viewing the detailed overview of Asymchem Laboratories Tianjin Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Asymchem Laboratories Tianjin Co (SZSE:002821) Business Description

Traded in Other Exchanges
Address
No. 6 Dongting Third Street, Economic and Technological Development Zone, Tianjin, CHN, 300457
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development Manufacture Organization solutions throughout the drug development and manufacturing process. The Group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing which focuses on innovation and commercial application of global pharmaceutical technology.
Executives
Xiao Yi Executives
Xu Xiang Ke Directors, executives
Zhou Yan Executives
Chen Chao Yong Executives
Huang Xiao Lian Executives
Yang Jing Director
Executives

Asymchem Laboratories Tianjin Co (SZSE:002821) Headlines

No Headlines